Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.

Bilezikian JP, Hattersley G, Fitzpatrick LA, Harris AG, Shevroja E, Banks K, Leder BZ, Zanchetta JR, Hans D

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA22 Nov 2017Cited by 48 (Europe PMC)

PMID29167971PMCIDPMC5818587DOI10.1007/s00198-017-4304-9PepBankPUB-29167971

Read at source PubMedAsk about this study

Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

01HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, abaloparatide 20 μg increased trabecular bone score from baseline.
In plain wordsIn postmenopausal women, abaloparatide 20 μg increased the bone structure score from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS change at 20 μg
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
TBS change
2.27%
20 μg at 24 weeks
Source sentences
Summary
After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p < 0.05 for each).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797101
02HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, abaloparatide 40 μg increased trabecular bone score from baseline.
In plain wordsIn postmenopausal women, abaloparatide 40 μg increased the bone structure score from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS change at 40 μg
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
TBS change
3.14%
40 μg at 24 weeks
Source sentences
Summary
After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p < 0.05 for each).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797102
03HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, abaloparatide 80 μg increased trabecular bone score from baseline.
In plain wordsIn postmenopausal women, abaloparatide 80 μg increased the bone structure score from baseline.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS change at 80 μg
Study
n: not reported in source
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg daily · subcutaneous · 24 weeksAs given in this study (human).
Measurements
TBS change
4.21%
80 μg at 24 weeks
Source sentences
Summary
After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p < 0.05 for each).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797103
04HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, abaloparatide 20 μg increased TBS more than placebo after baseline adjustment.
In plain wordsIn postmenopausal women, abaloparatide 20 μg increased the bone structure score more than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS versus placebo at 20 μg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20 μg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The TBS increase in each treatment group was significantly higher than placebo at 24 weeks (p < 0.0001 for each) after adjustment for age, BMI, and baseline TBS.
3 context sentences(design, population, supporting numbers)
Summary · context
After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p < 0.05 for each).
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797104
05HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, abaloparatide 40 μg increased TBS more than placebo after baseline adjustment.
In plain wordsIn postmenopausal women, abaloparatide 40 μg increased the bone structure score more than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS versus placebo at 40 μg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
40 μg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The TBS increase in each treatment group was significantly higher than placebo at 24 weeks (p < 0.0001 for each) after adjustment for age, BMI, and baseline TBS.
3 context sentences(design, population, supporting numbers)
Summary · context
After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p < 0.05 for each).
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797105
06HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, abaloparatide 80 μg increased TBS more than placebo after baseline adjustment.
In plain wordsIn postmenopausal women, abaloparatide 80 μg increased the bone structure score more than placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS versus placebo at 80 μg
Study
n: not reported in source
Comparator
Placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The TBS increase in each treatment group was significantly higher than placebo at 24 weeks (p < 0.0001 for each) after adjustment for age, BMI, and baseline TBS.
3 context sentences(design, population, supporting numbers)
Summary · context
After 24 weeks, TBS increased significantly by 2.27, 3.14, and 4.21% versus baseline in participants on 20, 40, and 80 μg abaloparatide-SC daily, respectively, and by 2.21% in those on teriparatide (p < 0.05 for each).
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797106
07HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, TBS showed a dose-response across abaloparatide doses and placebo.
In plain wordsIn postmenopausal women, the bone structure score showed a dose response across abaloparatide doses and placebo.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS dose response
Study
n: not reported in source
Comparator
Other abaloparatide doses and placebo
Outcome group
Bone and joint · Musculoskeletal
Studied dose
20, 40, or 80 μg · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
A dose-response was observed at 24 weeks across the three doses of abaloparatide-SC and placebo (p = 0.02).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797107
08HumanRandomized controlled trialEfficacy outcome
In postmenopausal women, abaloparatide 80 μg increased TBS more than teriparatide.
In plain wordsIn postmenopausal women, abaloparatide 80 μg increased the bone structure score more than teriparatide.
Peptide
Abaloparatide (Tymlos)
Outcome
IncreaseTBS versus teriparatide
Study
n: not reported in source
Comparator
Teriparatide
Outcome group
Bone and joint · Musculoskeletal
Studied dose
80 μg daily · subcutaneous · 24 weeksAs given in this study (human).
Source sentences
Summary
The increase in TBS in the abaloparatide-SC 80 μg group was significantly greater than TPTD (p < 0.03).
2 context sentences(design, population, supporting numbers)
Summary · context
This is a post hoc analysis of a phase 2 trial of 222 postmenopausal women with osteoporosis aged 55 to 85 years randomized to abaloparatide-SC (20, 40, or 80 μg), subcutaneous teriparatide (20 μg), or placebo for 24 weeks.
Summary · context
TBS was measured from lumbar spine dual X-ray absorptiometry (DXA) images in 138 women for whom the DXA device was TBS software compatible.
Report a problemFND-2916797108

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
22 Oct 2026, 02:25 UTC
Study results updated
Version 1
21 Oct 2026, 18:59 UTC
First added · source update from Europe PMC

PepBank is a research reference. Talk to a doctor before you use any peptide.

Abaloparatide-SC improves trabecular microarchitecture as assessed by trabecular bone score (TBS): a 24-week randomized clinical trial.

Summary

Results from this study8

Version history

Subjects

Publication types

MeSH terms

Keywords